Discrete Improvement in Racial Disparity in Survival among Patients with Stage IV Colorectal Cancer: a 21-Year Population-Based Analysis

[1]  M. Hollands,et al.  A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[2]  R. Berger,et al.  Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location , 2013, Cancer.

[3]  M. Hollands,et al.  A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[4]  G. Lanke,et al.  Mo1143 Is Lymph Node Ratio (LNR) a Prognostic Marker in Patients With Colon Cancer? A Study in National Cancer Institute's Surveillance Epidemiology, and End Results (SEER) Database , 2013 .

[5]  C. Gross,et al.  Toxicity of bevacizumab in combination with chemotherapy in older patients. , 2013, The oncologist.

[6]  S. Gapstur,et al.  Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[8]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[9]  R. Greil,et al.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[10]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Jemal,et al.  Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Mithat Gönen,et al.  Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Saliba,et al.  Impact of Expanding Criteria for Resectability of Colorectal Metastases on Short- and Long-Term Outcomes After Hepatic Resection , 2011, Annals of surgery.

[14]  T. Eberlein.  Hospital Factors and Racial Disparities in Mortality After Surgery for Breast and Colon Cancer , 2011 .

[15]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Mullins,et al.  Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. , 2010, The American journal of managed care.

[17]  Adeyinka O Laiyemo,et al.  Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. , 2010, Journal of the National Cancer Institute.

[18]  C. Flowers,et al.  A black‐white comparison of the quality of stage‐specific colon cancer treatment , 2010, Cancer.

[19]  W. Hohenberger,et al.  Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[21]  Stephen B. Thomas,et al.  Trust in the health care system and the use of preventive health services by older black and white adults. , 2009, American journal of public health.

[22]  V. Rusch,et al.  Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. , 2009, The Annals of thoracic surgery.

[23]  Xianglin L. Du,et al.  Racial disparities and treatment trends in a large cohort of elderly African Americans and Caucasians with colorectal cancer, 1991 to 2002 , 2008, Cancer.

[24]  H. Bismuth,et al.  Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases , 2008, Annals of surgery.

[25]  Amy Y. Chen,et al.  Association of Insurance Status and Ethnicity With Cancer Stage at Diagnosis for 12 Cancer Sites: A Retrospective Analysis , 2008 .

[26]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[27]  Amy Y. Chen,et al.  Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. , 2008, The Lancet. Oncology.

[28]  R. Parks,et al.  Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC Intergroup trial 40983 ) : a randomised controlled trial , 2008 .

[29]  F. Hu,et al.  Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. , 2007, JAMA.

[30]  R. Adam.  Developing strategies for liver metastases from colorectal cancer. , 2007, Seminars in oncology.

[31]  Wei Zhang,et al.  Patient characteristics and hospital quality for colorectal cancer surgery. , 2007, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[32]  B. Kennedy,et al.  African Americans and their distrust of the health care system: healthcare for diverse populations. , 2007, Journal of cultural diversity.

[33]  E. Ellerbeck,et al.  Disparities in colorectal cancer screening: a guideline-based analysis of adherence. , 2006, Ethnicity & disease.

[34]  Graham A Colditz,et al.  Physical activity and survival after colorectal cancer diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Nancy Breen,et al.  Patterns of Colorectal Cancer Screening Uptake among Men and Women in the United States , 2006, Cancer Epidemiology Biomarkers & Prevention.

[36]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[37]  Nancy Breen,et al.  Progress in cancer screening practices in the United States , 2003, Cancer.

[38]  V. Shavers,et al.  Racial and ethnic disparities in the receipt of cancer treatment. , 2002, Journal of the National Cancer Institute.

[39]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .